Health
Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra® (resmetirom)Analysis of two-year data in patients with compensated MASH cirrhosis (F4c) examines improvement in ANTICIPATE-NASH risk scores, a marker for clinically significant portal hypertensionAdditional abstracts focus on early real-world evidence with Rezdiffra and the ability of noninvasive biomarkers to predict fibrosis improvement i
About this update from Madrigal Pharmaceuticals, Inc.
[{"type":"image","alt":"Madrigal Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Madrigal Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/0a35449b0ee323b8224d49bf845d4cf5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cN2_C_I.OrsxKBO.PLoAhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMA--/https://media.zenfs.com/en/globenewswire.com/0a35449b0ee323b8224d49bf845d4cf5","width":300,"height":86},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/cN2_C_I.OrsxKBO.PLoAhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMA--/https://media.zenfs.com/en/globenewswire.com/0a35449b0ee323b8224d49bf845d4cf5","width":300,"height":86}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra® (resmetirom)","length":170,"tagName":"p"}]},{"val":[{"type":"text","content":"Analysis of two-year data in patients with compensated MASH cirrhosis (F4c) examines improvement in ANTICIPATE-NASH risk scores, a marker for clinically significant portal hypertension","length":184,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional abstracts focus on early real-world evidence with Rezdiffra and the ability of noninvasive biomarkers to predict fibrosis improvement in patients treated with Rezdiffra","length":179,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":533,"olType":false},{"type":"text","content":"CONSHOHOCKEN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that multiple abstracts from its Rezdiffra development and real-world evidence programs will be presented at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27–30 in Barcelona, Spain.","length":471,"tagName":"p"},{"type":"text","content":"The presentations highlight the breadth of evidence supporting Rezdiffra, including a secondary analysis on cardiometabolic risk in patients with MASH, non-invasive risk stratification in patients with compensated cirrhosis and early real-world evidence fro...